Longevity Stocks

Track and analyze the world's leading aging research and life extension companies

# Company Price Market Cap Longevity Angle Tags
1
Vertex Pharmaceuticals Incorporated
VRTX
$473.3768 $121.91B Gene editing and age-related disease treatments Gene Therapy Disease Treatment Biotech
2
Seagen Inc.
SGEN
$228.74 $43.15B Targeted therapies for age-related cancers Cancer Antibodies Research
3
Alnylam Pharmaceuticals, Inc.
ALNY
$273.49 $35.28B RNA therapeutics for age-related conditions RNA Therapeutics Research
4
BioNTech SE
BNTX
$119.955 $28.76B mRNA technology for age-related diseases mRNA Therapeutics Research
5
BeiGene, Ltd.
BGNE
$184.71 $20.21B Novel therapeutics for age-related diseases Cancer Therapeutics Research
6
Ionis Pharmaceuticals, Inc.
IONS
$32.55 $5.14B RNA-targeted therapeutics for aging diseases RNA Drug Development Research
7
CRISPR Therapeutics AG
CRSP
$40.79 $3.48B CRISPR gene editing for age-related diseases Gene Editing CRISPR Therapeutics
8
Denali Therapeutics Inc.
DNLI
$22.52 $3.24B Neurodegenerative disease treatments Neurodegeneration Brain Health Research
9
Beam Therapeutics Inc.
BEAM
$27.72 $2.30B Base editing technology for genetic diseases Base Editing Genetics Research
10
Verve Therapeutics, Inc.
VERV
$8.43 $713.72M Gene editing for cardiovascular disease Gene Editing Heart Disease Research
11
Sage Therapeutics, Inc.
SAGE
$7.24 $442.89M Brain health and aging-related disorders Brain Health Neuroscience Research
12
Allogene Therapeutics, Inc.
ALLO
$1.58 $331.28M Allogeneic cell therapy for longevity Cell Therapy Cancer Research
13
Fate Therapeutics, Inc.
FATE
$1.35 $153.76M Cell therapy for regenerative medicine Cell Therapy Regenerative Research
14
Editas Medicine, Inc.
EDIT
$1.285 $106.07M Gene editing platform for age-related conditions Gene Editing Therapeutics Research
15
bluebird bio, Inc.
BLUE
$6.6 $64.17M Gene therapy for age-related conditions Gene Therapy Rare Disease Research
16
Longeveron Inc.
LGVN
$1.62 $24.04M Regenerative medicine and anti-aging research Regenerative Anti-aging Research
17
Frequency Therapeutics, Inc.
FREQ
$0.2996 $10.94M Regenerative medicine for hearing loss Regenerative Hearing Research
18
Applied Genetic Technologies Corporation
AGTC
$0.3936 $- Gene therapy for age-related eye diseases Gene Therapy Eye Disease Research

VRTX ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Vertex Pharmaceuticals Incorporated

NEW YORK, NY / ACCESS Newswire / February 7, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex Pharmaceuticals Incorporated ("Vertex Pharmaceuticals") (NASDAQ:VRTX) concerning possible violations of federal securities laws. On December 19, 2024, the company reported disappointing results from its RewinD-LB Phase 2b clinical trial for the pain drug suzetrigine.

News image

Denali Therapeutics Announces Primary Analysis and Long-Term Follow-Up of Phase 1/2 Study in Hunter Syndrome (MPS II) with Tividenofusp Alfa

SOUTH SAN FRANCISCO, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), today announced the primary analysis of the Phase 1/2 study in 47 participants with Hunter syndrome (MPS II) in the 24-week treatment period and additional long-term follow-up of its investigational therapeutic tividenofusp alfa (DNL310). These data, along with recent Breakthrough Therapy designation, further support the company's plan to submit a biologics license application (BLA) in early 2025 for accelerated approval and deliver this potential treatment to the Hunter syndrome community in late 2025 or early 2026. The Phase 1/2 results are being presented this week at the 21st Annual WORLDSymposium™ conference in San Diego, California.

News image

Alnylam Pharmaceuticals (ALNY) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Alnylam (ALNY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

News image

ATTENTION VRTX SHAREHOLDERS: Investors who Lost Money on Vertex Pharmaceuticals Incorporated are Urged to Contact Levi & Korsinsky About an Ongoing Investigation

NEW YORK, NY / ACCESS Newswire / February 6, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex Pharmaceuticals Incorporated ("Vertex Pharmaceuticals") (NASDAQ:VRTX) concerning possible violations of federal securities laws. On December 19, 2024, the company reported disappointing results from its RewinD-LB Phase 2b clinical trial for the pain drug suzetrigine.

News image

CRISPR Therapeutics AG (CRSP) Guggenheim SMID Cap Biotech Conference (Transcript)

CRISPR Therapeutics AG (NASDAQ:CRSP ) Guggenheim SMID Cap Biotech Conference Transcript February 6, 2025 2:00 PM ET Company Participants Samarth Kulkarni - Chief Executive Officer Conference Call Participants Debjit Chattopadhyay - Guggenheim Partners Debjit Chattopadhyay And thank you for joining Guggenheim during our second SMID Cap conference. I am Debjit, one of the therapeutic analysts here, and joining me from CRISPR Therapeutics is CEO, Samarth Kulkarni.

News image

Crispr Therapeutics: Why I've Become Even More Bullish (Rating Upgrade)

Crispr Therapeutics AG's partnership with Vertex Pharmaceuticals offers financial support, mentorship, and validation, enhancing Crispr's approach and technology. Despite slower-than-expected Casgevy enrollment, Crispr's strong cash position and diversified drug pipeline bolster its long-term growth potential. Clinical progress includes expanding authorized treatment centers for Casgevy and advancing multiple drug candidates in hemoglobinopathies, CAR-T, and in vivo programs.

News image

Final Trades: Energy Transfer, Vertex Pharma, UnitedHealth and Axon Enterprise

The Investment Committee give you their top stocks to watch for the second half.

News image

Is VRTX a Portfolio Must Have After Two FDA Nods Ahead of Q4 Earnings?

On Vertex's Q4 earnings call, investors will focus on management's comments about launch preparation for Alyftrek (vanza triple) and Journavx (suzetrigine).

News image

Unlocking Q4 Potential of Vertex (VRTX): Exploring Wall Street Estimates for Key Metrics

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Vertex (VRTX), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2024.

News image

An Investigation Has Commenced on Behalf of Vertex Pharmaceuticals Incorporated Shareholders. Contact Levi & Korsinsky to Discuss your VRTX Losses.

NEW YORK, NY / ACCESS Newswire / February 5, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex Pharmaceuticals Incorporated ("Vertex Pharmaceuticals") (NASDAQ:VRTX) concerning possible violations of federal securities laws. On December 19, 2024, the company reported disappointing results from its RewinD-LB Phase 2b clinical trial for the pain drug suzetrigine.

News image

Ionis to hold fourth quarter and full year 2024 financial results webcast

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, February 19th at 11:30 a.m. Eastern Time to discuss its fourth quarter and full year 2024 financial results. The webcast may be accessed at https://ir.ionis.com/events-and-presentations/upcoming-events. A replay will be available for a limited time at the same address. About Ionis Pharmaceuticals, Inc. For three decades, Ionis has invented medicines that b.

News image

Why CRISPR Therapeutics AG (CRSP) Outpaced the Stock Market Today

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $40.49, marking a +1.23% move from the previous day.

News image

VRTX STOCK ALERT: Levi & Korsinsky Notifies Vertex Pharmaceuticals Incorporated Investors of an Ongoing Investigation

NEW YORK, NY / ACCESS Newswire / February 4, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex Pharmaceuticals Incorporated ("Vertex Pharmaceuticals") (NASDAQ:VRTX) concerning possible violations of federal securities laws. On December 19, 2024, the company reported disappointing results from its RewinD-LB Phase 2b clinical trial for the pain drug suzetrigine.

News image

Vertex Pharma Just Scored a Major FDA Approval. Is the Stock a No-Brainer Buy Now?

Vertex Pharmaceuticals (VRTX) has long been known as the company to turn to for life-saving cystic fibrosis (CF) drugs, and this platform has helped it generate billions of dollars in earnings. But Vertex now is showing that it also can be a game changer when it comes to treating one of the most common of health problems -- pain.

News image

Vertex Pharmaceuticals (VRTX) Ascends While Market Falls: Some Facts to Note

In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $470.37, marking a +1.88% move from the previous day.

News image

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on January 31, 2025, the company granted equity awards to eight new employees, pursuant to the company's 2024 Inducement Stock Incentive Plan, as an inducement material to each new employee entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).

News image

Vertex (VRTX) Surges 5.3%: Is This an Indication of Further Gains?

Vertex (VRTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

News image

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

News image

3 Magnificent Stocks to Buy and Hold Forever

Some people are fair-weather friends; others are lifelong. It's a similar story with stocks.

News image

Are These 5 Biotech Stocks Set to Beat Q4 Earnings Estimates?

Let us look at some biotech stocks, AMGN, CRSP, MRNA, SRPT and VRTX, which are poised to beat on fourth-quarter earnings.

News image

Are These 5 Biotech Stocks Set to Beat Q4 Earnings Estimates?

Let us look at some biotech stocks, AMGN, CRSP, MRNA, SRPT and VRTX, which are poised to beat on fourth-quarter earnings.

News image

Bet on These 4 Top-Performing Liquid Stocks for Solid Gains

Investors can boost returns by adding these top-ranked liquid stocks, Alnylam Pharmaceuticals, Frontdoor, EverQuote and Sezzle, to their portfolios.

News image

Lost Money on Vertex Pharmaceuticals Incorporated(VRTX)? You May Have Been Affected by Fraud- Contact Levi & Korsinsky

NEW YORK, NY / ACCESS Newswire / February 3, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex Pharmaceuticals Incorporated ("Vertex Pharmaceuticals") (NASDAQ:VRTX) concerning possible violations of federal securities laws. On December 19, 2024, the company reported disappointing results from its RewinD-LB Phase 2b clinical trial for the pain drug suzetrigine.

News image

Vertex Pharmaceuticals Just Won a Huge FDA Approval. Is the Biotech Stock a No-Brainer Buy?

Vertex Pharmaceuticals (VRTX 5.31%) just snagged its second U.S. Food and Drug Administration (FDA) approval in only 41 days. On Dec. 20, 2024, the FDA gave a thumbs-up to Alyftrek in treating cystic fibrosis (CF).

News image

Is Vertex Pharmaceuticals a Buy Now That the FDA Approved Its New Pain Drug?

Lately, one of America's leading pharmaceutical companies can't catch a break from Wall Street. Shares of Vertex Pharmaceuticals (VRTX 5.31%) are down about 9% from a peak the stock set in November, despite some highly positive news.

News image

Vertex: Maintaining Buy Despite Tempered Expectations For Journavx In Pain

Vertex's Journavx got FDA approval for acute pain but faces adoption challenges: variable efficacy vs opioids, generic competition, and entrenched prescriber habits limit near-term potential. Phase 2 LSR trial showed minimal benefit vs placebo, raising concerns about $11B peak sales estimates and success in ongoing diabetic neuropathy trial (completion in 2027). Conservative market expectations: Acute pain market $10-20B; $1.5B sales (10% share) more realistic. Must compete with established generics in neuropathic pain market.

News image

Vertex: YOY Decline In Q4 Earnings Expected, But Revenue Continues To Shine

Expectation is a decline in Vertex's earnings, but double-digit revenue growth should continue with the newly approved non-opioid drug JOURNAVX and CF franchise expansion. JOURNAVX, the first non-opioid oral pain signal inhibitor approved in over 20 years, targets a large market, potentially boosting Vertex's revenue significantly over time. The company's CF franchise continues to expand with new approvals and treatments, including TRIKAFTA, ALYFTREK, and VX-522, targeting a broader patient base.

News image

Vertex Pharma Stock Surges After FDA Approves Non-Opioid Pain Drug

JOURNAVX, a non-opioid analgesic, shows significant promise in treating pain with a superior safety profile, addressing a critical unmet need compared to opioids with FDA approval just announced. Vertex Pharmaceuticals continues to execute its commercialization of three new drugs, JOURNAVX, CASGEVY, and ALYFTREK. Two of which have been approved by the FDA since December. Vertex's valuation appears high due to recent expenses, but analysts expect substantial earnings growth in 2025 as acquisition and clinical expenses subside.

News image

VRTX Gets FDA Nod for Non-Opioid Pain Drug Journavx, Shares Up

The FDA approves Vertex's non-opioid oral pain signal inhibitor, Journavx, for treating adults with moderate-to-severe acute pain. Shares rise.

News image

FDA approves a new painkiller for the first time in decades

Vertex Pharmaceuticals' non-opioid painkiller comes without the potential risk of addiction. Transcript: Conway Gittens: Wall Street heads into the weekend with modest strength - and that's no small feat given how the week began.

News image

Biotech Stock Rises After FDA Approves Non-Opioid Painkiller

Vertex Pharmaceuticals Inc (NASDAQ:VRTX) stock is up 6% at $465.02 at last glance, after the U.S. Food and Drug Administration (FDA) approved the biotech's new non-opioid painkiller, Journavx.

News image

Kuehn Law Encourages Investors of Verve Therapeutics, Inc. to Contact Law Firm

NEW YORK , Jan. 31, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Verve Therapeutics, Inc. (NASDAQ: VERV) breached their fiduciary duties to shareholders.  The investigation concerns potential self-dealing.

News image

Vertex Pharmaceuticals Stock Jumps as Non-Opioid Painkiller Gets FDA Approval

Shares of Vertex Pharmaceuticals (VRTX) surged Friday, a day after the drugmaker reported federal regulators have approved its non-opioid painkiller, the first such drug to head to market in two decades.

News image

Vertex Pharmaceuticals CEO on non-opioid painkiller: It's safe, effective and non-addictive

CNBC's Angelica Peebles and Vertex JournavxPharmaceuticals CEO Reshma Kewalramani join 'Squawk on the Street' to discuss the FDA's approval of the company's non-opioid painkiller pill Journavx, a new alternative for pain relief that comes without the risk of addiction, concerns around drug effectiveness and costs, and more.

News image

What's Happening With VRTX Stock?

Vertex Pharmaceuticals stock (NASDAQ: VRTX) is trending higher after the U.S. FDA approved Journavx – an oral non-opioid pain medication. This is a big win for Vertex, given that Journavx can potentially garner $4 billion in annual peak sales.

News image

Vertex Pharmaceuticals Incorporated Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - VRTX

NEW YORK, NY / ACCESS Newswire / January 31, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex Pharmaceuticals Incorporated ("Vertex Pharmaceuticals") (NASDAQ:VRTX) concerning possible violations of federal securities laws. On December 19, 2024, the company reported disappointing results from its RewinD-LB Phase 2b clinical trial for the pain drug suzetrigine.

News image

Vertex Pharmaceuticals Stock Jumps After FDA Approval for New Non-Opioid Painkiller

Journavx is the first and only approved non-opioid oral painkiller and the first new class of pain medicine approved in more than 20 years.

News image

FDA approves Vertex's non-opioid painkiller, first new kind of pain medicine in decades

CNBC's Becky Quick reports on the latest news.

News image

Vertex Pharmaceuticals stock is soaring. The FDA just approved its potentially game-changing pain treatment.

Shares of Vertex Pharmaceuticals Inc. surged ahead of Friday's market open after the Food and Drug Administration approved the company's non-opioid pain treatment.

News image

Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease in England

LONDON--(BUSINESS WIRE)--Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with NHS England for eligible sickle cell disease (SCD) patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY® (exagamglogene autotemcel). The reimbursement agreement comes as the National Institute for Health and Care Excellence (NICE) issues positive guidance recommending CASGEVY's use in the NHS. It means that eligible SCD patients in England now have access to the therapy follo.

News image

FDA Approves Non-Opioid Painkiller With No Addiction Risk

The Food and Drug Administration approved Vertex Pharmaceuticals' “Journavx” on Thursday, greenlighting the non-opioid painkiller for treating moderate to severe pain in what the FDA considered the start of a new class of non-addictive medicines.

News image

Vertex Pharmaceuticals Jumps On FDA Approval For Non-Opioid Painkiller

Vertex Pharmaceuticals won FDA approval for its non-opioid painkiller Journavx. Vertex stock jumped in late trading.

News image

Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved JOURNAVX™ (suzetrigine), an oral, non-opioid, highly selective NaV1.8 pain signal inhibitor for the treatment of adults with moderate-to-severe acute pain. JOURNAVX is an effective, well-tolerated medicine without evidence of addictive potential indicated for use across all types of moderate-to-severe acute pain. “Today's approval is a histori.

News image

US FDA approves Vertex's non-opioid painkiller

The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals' drug to treat acute pain, the health regulator said on Thursday, offering an alternative to addictive opioid painkillers that have fueled a national crisis.

News image

FDA approves Vertex's non-opioid painkiller, first new kind of pain medicine in decades

The Food and Drug Administration approved Vertex Pharmaceuticals' non-opioid painkiller pill, a new alternative for pain relief that comes without the risk of addiction.  It's a milestone after a long history of unsuccessful efforts to develop painkillers without the destructive dependency of opioids, which have caused a horrific epidemic in the U.S.

News image

Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2024 Financial Results

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the fourth quarter and year ending December 31, 2024 on Thursday, February 13, 2025, before the U.S. financial markets open. Management will provide an update on the Company and discuss fourth quarter and year-end 2024 results as well as expectations for the future via conference call on Thursday, February 13, 2025 at 8.

News image

Investors who Lost Money on Vertex Pharmaceuticals Incorporated Should Contact Levi & Korsinsky About an Ongoing Investigation - VRTX

NEW YORK, NY / ACCESS Newswire / January 30, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex Pharmaceuticals Incorporated ("Vertex Pharmaceuticals") (NASDAQ:VRTX) concerning possible violations of federal securities laws. On December 19, 2024, the company reported disappointing results from its RewinD-LB Phase 2b clinical trial for the pain drug suzetrigine.

News image

Beam Therapeutics to Participate in Guggenheim SMID Cap Biotech Conference

CAMBRIDGE, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer of Beam, plans to participate in a fireside chat during the Guggenheim SMID Cap Biotech Conference on Thursday, February 6, 2025, at 2:30 p.m. ET in New York.

News image

CRISPR Therapeutics AG (CRSP) Declines More Than Market: Some Information for Investors

In the closing of the recent trading day, CRISPR Therapeutics AG (CRSP) stood at $41.21, denoting a -1.44% change from the preceding trading day.

News image

VRTX ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Vertex Pharmaceuticals Incorporated

NEW YORK, NY / ACCESS Newswire / January 29, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex Pharmaceuticals Incorporated ("Vertex Pharmaceuticals") (NASDAQ:VRTX) concerning possible violations of federal securities laws. On December 19, 2024, the company reported disappointing results from its RewinD-LB Phase 2b clinical trial for the pain drug suzetrigine.

News image

Verve Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference

BOSTON, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that Sekar Kathiresan, M.D., co-founder and chief executive officer, will participate in a fireside chat at the Guggenheim Securities SMID Cap Biotech Conference on Wednesday, February 5, 2025 at 9 a.m. ET in New York.

News image

Vertex Pharmaceuticals (VRTX) Stock Slides as Market Rises: Facts to Know Before You Trade

In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $440.68, marking a -0.72% move from the previous day.

News image

Frequently Asked Questions

Longevity technology encompasses:
  • Age-Related Disease Treatment - Targeting specific diseases of aging
  • Cellular Reprogramming - Reversing cellular aging processes
  • Gene Therapy - Modifying genes to extend lifespan
  • Regenerative Medicine - Repairing or replacing aged tissues
  • Aging Biomarkers - Measuring biological age and interventions

The leading longevity companies by market cap include:
  • VRTX - Vertex Pharmaceuticals Incorporated
  • SGEN - Seagen Inc.
  • ALNY - Alnylam Pharmaceuticals, Inc.
  • BNTX - BioNTech SE
  • BGNE - BeiGene, Ltd.

Major research areas include:
  • Senescent Cell Removal - Clearing aged, damaged cells
  • NAD+ Boosters - Enhancing cellular energy production
  • Stem Cell Therapy - Regenerating tissues and organs
  • Epigenetic Reprogramming - Resetting cellular age
  • Mitochondrial Enhancement - Improving cellular powerhouses
  • Telomere Extension - Protecting chromosome ends

Key investment considerations include:
  • Aging global population and healthcare demands
  • Breakthrough technologies in aging research
  • Growing private and public funding
  • Potential for revolutionary treatments
  • Multiple revenue streams (therapeutics, diagnostics, data)

Key factors affecting longevity stocks include:
  • Clinical trial results and FDA approvals
  • Research breakthroughs and patents
  • Partnership deals with major pharma
  • Regulatory environment for aging therapies
  • Healthcare policy and reimbursement
  • Competition and technological advances